Insights
Insights
Short founder essays that frame a problem, a principle, or an emerging strategic question in metabolic disease.
Insights
Insight · Diabetes
Disease Modification Arrives in Type 1 Diabetes
Teplizumab is the first disease-modifying therapy in type 1 diabetes — β-cell preservation is demonstrated, durable clinical benefit is not yet shown, and early detection is the binding constraint. Read the essay →
Insight
GLP-1's Forgotten Patients
GLP-1s won the average patient. The opening is everyone they leave behind. Read the essay →
Founder Essay
The Translational Gap in Metabolic Disease
Why metabolic care and evidence fragment even when biology is integrated. Read the essay →More insights as the series develops.
A question worth thinking through together?
For confidential biotech, spinout, investor, or strategic diligence inquiries, start with a brief scoping conversation.
Request a confidential scoping callPrefer email? [email protected]